Description

AOD9604 200mcg x 60

Clinicly proven to hit that belly role and remove stubborn faf along with lots of anti Ageing benefits.

Details of each study are listed in the supplemental data. The first 3 studies were dose escalation studies examining the acute effects of different doses and two routes of administration (i.v. and oral) in healthy or obese men. These single-dose studies were followed by a 7-day multiple-dose study (METAOD004), and two long-term clinical trials (METAOD005 and METAOD006) investigating the safety and tolerability of chronic oral treatment with AOD9604. Serum IGF-1 levels remained relatively constant over the dosing period, with no apparent differences between treatment groups.

Fasting plasma glucose and serum insulin levels remained unchanged throughout the treatment period. Overall, treatment of obese patients for 24 weeks with daily doses of 0.25 mg to 1 mg of AOD9604 showed a good safety and tolerability profile that was indistinguishable from placebo. AOD9604 supplementation did not worsen glucose control or induce insulin resistance. In contrast, AOD9604 treatment appeared to have a positive effect in patients with impaired glucose tolerance. In a 12-week study, patients with impaired glucose tolerance supplemented with AOD9604 were less likely to develop diabetes during the study than those taking placebo. However, this hypothesis needs to be confirmed in a separate clinical trial. In contrast, in a recent clinical trial of the effects of hGH on obese women, hGH increased IGF-1 levels over a 6-month dosing period and reduced glucose tolerance in a subgroup of study participants.